Abstract:Objective Our purpose is to unveil Andrographolide's potential multi-target and multi-mechanism therapeutic effects in treating OA via systematic network pharmacological analysis and cell experimental validation. Materials and Methods Initially, we gathered data from Andrographolide and OA-related databases to obtain information on Andrographolide's biological properties and the targets linked with OA. We developed a bioinformatic network about Andrographolide and OA, whereby we analyzed the network to identify potential therapeutic targets and mechanisms of action of Andrographolide. Subsequently, we used molecular docking to analyze the binding sites of Andrographolide to the target proteins. At the same time, SDF-1 was used to construct an OA cell model to verify the therapeutic effect of Andrographolide on OA and its effect on target proteins. Results Our experimental results show that Andrographolide has excellent pharmaceutical properties, by Lipinski's rules for drugs, suggesting that this compound can be considered to have a high therapeutic potential in drug development. 233 targets were preliminarily investigated, the mechanisms through which Andrographolide targets OA primarily involve the TNF signaling pathway, PI3K-AKT signaling pathway, IL-17 signaling pathway, and TLR signaling pathway. These mechanisms target OA by influencing immune and inflammatory responses in the joints, regulating apoptosis to prevent chondrocyte death. Finally, TNF-α, STAT3, TP53, IL-6, JUN, IL-1β, HIF-1α, TGF-β1, and AKT1 were identified as 9 key targets of Andrographolide anti-OA. In addition, our molecular docking analyzes with cell experimental validation further confirm the network pharmacology results. According to our molecular docking results, Andrographolide can bind to all the hub target proteins and has a good binding ability (binding energy < -5 kcal/mol), with the strongest binding affinity to AKT1 of −9.2 kcal/ mol. The results of cell experiments showed that Andrographolide treatment significantly increased the cell viability and the expression of COL2A1 and ACAN proteins. Moreover, 30 μM Andrographolide significantly reversed SDF-1-induced increases in the protein expression of TNF-α, STAT3, TP53, IL-6, JUN, IL-1β, HIF-1α, and TGF-β1, and decreases in the protein expression of AKT1. Conclusion This study provides a comprehensive understanding of the potential therapeutic targets and mechanisms of action of Andrographolide in OA treatment. Our findings suggest that Andrographolide is a promising candidate for drug development in the management of OA.

Andrographolide Exerts Pro-Osteogenic Effect by Activation of Wnt/β-Catenin Signaling Pathway in Vitro

Andrographolide Stimulates Osteoblastogenesis and Bone Formation by Inhibiting Nuclear Factor Kappa-Β Signaling Both in Vivo and in Vitro.

Andrographolide Suppresses Rankl-Induced Osteoclastogenesis in Vitro and Prevents Inflammatory Bone Loss in Vivo

Asperosaponin VI Promotes Bone Marrow Stromal Cell Osteogenic Differentiation Through the PI3K/AKT Signaling Pathway in an Osteoporosis Model

Synthesis and Evaluation of Andrographolide Derivatives As Potent Anti-Osteoporosis Agents in Vitro and in Vivo

Andrographolide Prevents Human Breast Cancer-Induced Osteoclastic Bone Loss Via Attenuated RANKL Signaling

Anagliptin stimulates osteoblastic cell differentiation and mineralization

Ginkgolide B Promotes Osteoblast Differentiation Via Activation of Canonical Wnt Signalling and Alleviates Osteoporosis Through a Bone Anabolic Way

Angelica polysaccharide promotes proliferation and osteoblast differentiation of mesenchymal stem cells by regulation of long non-coding RNA H19: An animal study

Apigenin promotes osteogenic differentiation of mesenchymal stem cells and accelerates bone fracture healing via activating Wnt/β-catenin signaling.

Epimedium Aqueous Extract Improves Osteoporosis and Regulates PPARgamma, GSK-3-Beta and Beta-Catenin Expression in Ovariectomized Rats

Elucidation of the key therapeutic targets and potential mechanisms of Andrographolide multi-targets against osteoarthritis via network pharmacological analysis and experimental validation

Apelin-13 induces mitophagy in bone marrow mesenchymal stem cells to suppress intracellular oxidative stress and ameliorate osteoporosis by activation of AMPK signaling pathway

Pilose antler peptide promotes osteoblast proliferation, differentiation and mineralization via the insulin signaling pathway

Preptin Promotes Proliferation and Osteogenesis of MC3T3‐E1 Cells by Upregulating Β‐catenin Expression

Epimedium Aqueous Extract Improves Osteoporosis and Regulates PPARγ, GSK-3β and β-Catenin Expression in Ovariectomized rats

Astragaloside Ii Induces Osteogenic Activities of Osteoblasts Through the Bone Morphogenetic Protein-2/Mapk and Smad1/5/8 Pathways

Amyloid β peptide promotes bone formation by regulating Wnt/β-catenin signaling and the OPG/RANKL/RANK system.

Network Pharmacology-Based Strategy for the Investigation of the Anti-Osteoporosis Effects and Underlying Mechanism of Zhuangguguanjie Formulation

Aloe polysaccharide promotes osteogenesis potential of adipose-derived stromal cells via BMP-2/Smads and prevents ovariectomized-induced osteoporosis

An Experimental Study on the Treatment of Osteoporosis with Andriol in Male Rats